Home › Research › Digital health tools
Dissociation of Down syndrome and Alzheimer's disease effects with imaging
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC et al.. Alzheimer's & dementia (New York, N. Y.), 2016-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Down Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)-like amyloid plaques and tangles and a high incidence of dementia and could provide an enriched population to study AD-targeted treatments. However, to evaluate effects of therapeutic intervention, it is necessary to dissociate the contributions of DS and AD from overall phenotype. Imaging biomarkers offer the potential to characterize and stratify patients who will worsen clinically but have yielded mixed findings in DS subjects. Methods We evaluated 18F fluorodeoxyglucose positron emission tomography (PET), florbetapir PET, and structural magnetic resonance (sMR) image data from 12 nondemented DS adults using advanced multivariate machine learning methods. Results Our results showed distinctive patterns of glucose metabolism and brain volume enabling dissociation of DS and AD effects. AD-like pattern expression corresponded to amyloid burden and clinical measures. Discussion These findings lay groundwork to enable AD clinical trials with characterization and disease-specific tracking of DS adults.
What this study adds
Evidence grade: Low
In 12 non-demented adults with Down syndrome, imaging showed distinctive patterns of glucose metabolism and brain volume that could separate Down syndrome and Alzheimer's disease effects. This lays groundwork for clinical trials but does not itself treat, cure or prevent Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Matthews, D. C., Lukic, A. S., Andrews, R. D., Marendic, B., Brewer, J., Rissman, R. A., et al. (2016). Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1016/j.trci.2016.02.004
Vancouver
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, et al. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimer's & dementia (New York, N. Y.). 2016. doi:10.1016/j.trci.2016.02.004. PMID: 28642933.
BibTeX
@article{matthews2016-28642933,
author = {Matthews, D. C. and Lukic, A. S. and Andrews, R. D. and Marendic, B. and Brewer, J. and Rissman, R. A. and Mosconi, L. and Strother, S. C. and others},
title = {{Dissociation of Down syndrome and Alzheimer's disease effects with imaging}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2016},
doi = {10.1016/j.trci.2016.02.004},
pmid = {28642933},
url = {https://doi.org/10.1016/j.trci.2016.02.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, to evaluate effects of therapeutic intervention, it is necessary to dissociate the contributions of DS and AD from overall phenotype.
- Results Our results showed distinctive patterns of glucose metabolism and brain volume enabling dissociation of DS and AD effects.
- Discussion These findings lay groundwork to enable AD clinical trials with characterization and disease-specific tracking of DS adults.
Why it matters
In 12 non-demented adults with Down syndrome, imaging showed distinctive patterns of glucose metabolism and brain volume that could separate Down syndrome and Alzheimer's disease effects. This lays groundwork for clinical trials but does not itself treat, cure or prevent Alzheimer's disease.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 43 of the 96 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 58 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.8 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 3 / 6 | Cited 3.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Toronto: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28642933) |
| Free to read | 2 / 2 | Free to read |
| Points | 43 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 43 of the 96 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.trci.2016.02.004
- PubMed: 28642933
- Original source →
- Free full text: Alzheimer s & Dementia Translational Research & Clinical Interventions →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Digital health tools from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.